3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
9
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
45
Paclitaxel
42
Carboplatin
34
Bevacizumab
18
Specimen Handling
17
Letrozole
16
lenvatinib
13
Magnetic Resonance Spectroscopy
12
dostarlimab
11
Cisplatin
11
Biopsy
11
Taxes
10
olaparib
9
Fulvestrant
9
Doxorubicin
9
abemaciclib
8
Megestrol Acetate
8
Docetaxel
8
durvalumab
7
atezolizumab
7
Nivolumab
7
Gemcitabine
7
Blood Specimen Collection
7
palbociclib
6
Oxaliplatin
6
Observation
6
Fluorouracil
6
niraparib
5
Surveys and Questionnaires
5
Progestins
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
AZD9833
×
1 year
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled